Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment

Bioorganic & Medicinal Chemistry
2013.0

Abstract

Based on the roles of Raf1 and JNK1 in hepatocarcinoma development, scaffold-based drug design was employed to produce a series of compounds, which subsequently were synthesized and explored as potential dual inhibitors Raf1 and JNK1 kinases for anti-tumor treatment. The compound 1-(3-chloro-4-(6-ethyl-4-oxo-4H-chromen-2-yl)phenyl)-3-(4-chloro-phenyl)urea (3d) showed 66%, 67% and 13% inhibition rate at 50 μM against Raf1, JNK1 and p38-alpha, respectively, but no effect on ERK1 and ERK2, and inhibited the expression of pERK1/2 markedly and HepG2 cells proliferation with IC(50) at 8.3 μM. Furthermore, 3d showed lower toxicity against normal liver cell-lines QSG7701 and HL7702. Molecular docking study further showed that 3d can fit into binding domain of JNK1 and Raf1. Our data suggested the activities of 3d were associated with dual inhibition of JNK1 and Raf1 kinases.

DOI： 10.1016/j.bmc.2012.04.006

Knowledge Graph

Similar Paper

Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment
Bioorganic & Medicinal Chemistry 2013.0
Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors
Bioorganic & Medicinal Chemistry 2012.0
3,3-Dimethyl-1H-pyrrolo[3,2-g]quinolin-2(3H)-one derivatives as novel Raf kinase inhibitors
Med. Chem. Commun. 2012.0
Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives
European Journal of Medicinal Chemistry 2017.0
Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor
European Journal of Medicinal Chemistry 2008.0
Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity
European Journal of Medicinal Chemistry 2022.0
Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors
Bioorganic & Medicinal Chemistry 2022.0
Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors
European Journal of Medicinal Chemistry 2015.0
Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2011.0
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors
Bioorganic & Medicinal Chemistry Letters 2019.0